Substituted methcathinones differ in transporter and receptor interactions

Biochemical Pharmacology

Volumn 85, Issue 12, 2013, Pages 1803-1815

  Eshleman, Amy J ^a,b   Wolfrum, Katherine M ^a   Hatfield, Meagan G ^a   Johnson, Robert A ^a   Murphy, Kevin V ^a,b   Janowsky, Aaron ^a,b,c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dopamine transporter; Methcathinone; Norepinephrine transporter; Serotonin receptor; Serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4 FLUOROMETHCATHINONE; 4' METHYLMETHCATHINONE; AMPHETAMINE; BUTYLONE; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; COCAINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; METHCATHINONE DERIVATIVE; METHYLONE; NAPHYRONE; NEUROTRANSMITTER; NORADRENALIN TRANSPORTER; PSYCHOSTIMULANT AGENT; RADIOLIGAND; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SIGMA 1 OPIATE RECEPTOR; TRITIUM; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; NEUROTRANSMITTER RELEASE; NEUROTRANSMITTER UPTAKE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SUBSTITUTION REACTION;

BENZODIOXOLES; DESIGNER DRUGS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HEK293 CELLS; HUMANS; METHAMPHETAMINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PENTANONES; PROPIOPHENONES; PROTEIN BINDING; PYRROLIDINES; RECEPTORS, SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYMPORTERS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84878858007     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.04.004     Document Type: Article

References (54)

1. H.A. Spiller, M.L. Ryan, R.G. Weston, and J. Jansen Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States Clin Toxicol (Phila) 49 2011 499 505
2. J.M. Striebel, and J.M. Pierre Acute psychotic sequelae of "bath salts" Schizophr Res 133 2011 259 260
3. E.A. Ross, G.M. Reisfield, M.C. Watson, C.W. Chronister, and B.A. Goldberger Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone Am J Med 125 2012 854 858
4. J.P. Kelly Cathinone derivatives: a review of their chemistry, pharmacology and toxicology Drug Test Anal 3 2011 439 453
5. A. Derungs, S. Schietzel, M.R. Meyer, H.H. Maurer, S. Krahenbuhl, and M.E. Liechti Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylpyrovalerone) Clin Toxicol (Phila) 49 2011 691 693
6. L. Iversen, S. Gibbons, R. Treble, V. Setola, X.P. Huang, and B.L. Roth Neurochemical profiles of some novel psychoactive substances Eur J Pharmacol 700 2013 147 151
7. P.C. Meltzer, D. Butler, J.R. Deschamps, and B.K. Madras 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors J Med Chem 49 2006 1420 1432 (Pubitemid 43271895)
8. L. Simmler, T. Buser, M. Donzelli, Y. Schramm, L.H. Dieu, and J. Huwyler Pharmacological characterization of designer cathinones in vitro Br J Pharmacol 168 2013 458 470
9. R.A. Glennon, M. Yousif, N. Naiman, and P. Kalix Methcathinone: a new and potent amphetamine-like agent Pharmacol Biochem Behav 26 1987 547 551 (Pubitemid 17047729)
10. R. Young, and R.A. Glennon Cocaine-stimulus generalization to two new designer drugs: methcathinone and 4-methylaminorex Pharmacol Biochem Behav 45 1993 229 231
11. M.P. Gygi, A.E. Fleckenstein, J.W. Gibb, and G.R. Hanson Role of endogenous dopamine in the neurochemical deficits induced by methcathinone J Pharmacol Exp Ther 283 1997 1350 1355 (Pubitemid 28016510)
12. T.A. Dal Cason, R. Young, and R.A. Glennon Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs Pharmacol Biochem Behav 58 1997 1109 1116 (Pubitemid 28108223)
13. P.K. Huang, S.M. Aarde, D. Angrish, K.L. Houseknecht, T.J. Dickerson, and M.A. Taffe Contrasting effects of d-methamphetamine, 3,4- methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats Drug Alcohol Depend 126 2012 168 175
14. R. Lopez-Arnau, J. Martinez-Clemente, D. Pubill, E. Escubedo, and J. Camarasa Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone Br J Pharmacol 167 2012 407 420
15. H.M. Kamens, S. Burkhart-Kasch, C.S. McKinnon, N. Li, C. Reed, and T.J. Phillips Sensitivity to psychostimulants in mice bred for high and low stimulation to methamphetamine Genes Brain Behav 4 2005 110 125 (Pubitemid 40333315)
16. D.M. Camp, K.E. Browman, and T.E. Robinson The effects of methamphetamine and cocaine on motor behavior and extracellular dopamine in the ventral striatum of Lewis versus Fischer 344 rats Brain Res 668 1994 180 193
17. N.V. Cozzi, M.K. Sievert, A.T. Shulgin, P. Jacob III, and A.E. Ruoho Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines Eur J Pharmacol 381 1999 63 69 (Pubitemid 29488590)
18. F. Nagai, R. Nonaka, and K.K. Satoh Hisashi The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain Eur J Pharmacol 559 2007 132 137 (Pubitemid 46295399)
19. S. Yubero-Lahoz, M.A. Ayestas Jr., B.E. Blough, J.S. Partilla, R.B. Rothman, and R. de la Torre Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain Eur J Pharmacol 674 2012 337 344
20. M.H. Baumann, M.A. Ayestas Jr., J.S. Partilla, J.R. Sink, A.T. Shulgin, and P.F. Daley The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37 2012 1192 1203
21. I.T. Lee, S. Chen, and J.A. Schetz An unambiguous assay for the cloned human sigma1 receptor reveals high affinity interactions with dopamine D4 receptor selective compounds and a distinct structure-affinity relationship for butyrophenones Eur J Pharmacol 578 2008 123 136 (Pubitemid 350309585)
22. A.J. Eshleman, M. Carmolli, M. Cumbay, C.R. Martens, K.A. Neve, and A. Janowsky Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type J Pharmacol Exp Ther 289 1999 877 885 (Pubitemid 29191245)
23. M.B. Gatch, M.J. Forster, A. Janowsky, and A.J. Eshleman Abuse liability profile of three substituted tryptamines J Pharmacol Exp Ther 338 2011 280 289
24. C.J. Wilhelm, R.A. Johnson, P.G. Lysko, A.J. Eshleman, and A. Janowsky Effects of methamphetamine and lobeline on vesicular monoamine and dopamine transporter-mediated dopamine release in a cotransfected model system J Pharmacol Exp Ther 310 2004 1142 1151 (Pubitemid 39108936)
25. R.G. Staal, K.A. Hogan, C.L. Liang, D.C. German, and P.K. Sonsalla In vitro studies of striatal vesicles containing the vesicular monoamine transporter (VMAT2): rat versus mouse differences in sequestration of 1-methyl-4-phenylpyridinium J Pharmacol Exp Ther 293 2000 329 335 (Pubitemid 30244078)
26. H. Varoqui, and J.D. Erickson Functional identification of vesicular monoamine and acetylcholine transporters Methods Enzymol 296 1998 84 99 (Pubitemid 28455014)
27. A. Newman-Tancredi, S. Gavaudan, C. Conte, C. Chaput, M. Touzard, and L. Verriele Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study Eur J Pharmacol 355 1998 245 256 (Pubitemid 28404707)
28. A.R. Knight, A. Misra, K. Quirk, K. Benwell, D. Revell, and G. Kennett Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors Naunyn Schmiedebergs Arch Pharmacol 370 2004 114 123 (Pubitemid 39222863)
29. L. Toll, I.P. Berzetei-Gurske, W.E. Polgar, S.R. Brandt, I.D. Adapa, and L. Rodriguez Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications NIDA Res Monogr 178 1998 440 466
30. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem Pharmacol 22 1973 3099 3108
31. R.B. Rothman, J.S. Partilla, M.H. Baumann, C.M. Dersch, F.I. Carroll, and K.C. Rice Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse Synapse 35 2000 222 227 (Pubitemid 30056719)
32. B.M. Cawrse, B. Levine, R.A. Jufer, D.R. Fowler, S.P. Vorce, and A.J. Dickson Distribution of methylone in four postmortem cases J Anal Toxicol 36 2012 434 439
33. P.D. Maskell, P.G. De, C. Seneviratne, and D.J. Pounder Mephedrone (4-methylmethcathinone)-related deaths J Anal Toxicol 35 2011 188 191
34. J.M. Pearson, T.L. Hargraves, L.S. Hair, C.J. Massucci, C.C. Frazee III, and U. Garg Three fatal intoxications due to methylone J Anal Toxicol 36 2012 444 451
35. A.E. Fleckenstein, J.W. Gibb, and G.R. Hanson Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity Eur J Pharmacol 406 2000 1 13
36. N.D. Volkow, L. Chang, G.J. Wang, J.S. Fowler, M. Leonido-Yee, and D. Franceschi Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers Am J Psychiatry 158 2001 377 382 (Pubitemid 32205193)
37. N.D. Volkow, L. Chang, G.J. Wang, J.S. Fowler, Y.S. Ding, and M. Sedler Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex Am J Psychiatry 158 2001 2015 2021 (Pubitemid 33104107)
38. N. Granado, S. Ares-Santos, and R. Moratalla Methamphetamine and Parkinson's disease Parkinsons Dis 2013 2013 308052
39. M. Sparago, J. Wlos, J. Yuan, G. Hatzidimitriou, J. Tolliver, and T.A. Dal Cason Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse J Pharmacol Exp Ther 279 1996 1043 1052 (Pubitemid 27166883)
40. M. Angoa-Perez, M.J. Kane, D.I. Briggs, D.M. Francescutti, C.E. Sykes, and M.M. Shah Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine, and MDMA J Neurochem 125 2013 102 110
41. M. Angoa-Perez, M.J. Kane, D.M. Francescutti, K.E. Sykes, M.M. Shah, and A.M. Mohammed Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum J Neurochem 120 2012 1097 1107
42. G.C. Hadlock, K.M. Webb, L.M. McFadden, P.W. Chu, J.D. Ellis, and S.C. Allen 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse J Pharmacol Exp Ther 339 2011 530 536
43. J.M. Prosser, and L.S. Nelson The toxicology of bath salts: a review of synthetic cathinones J Med Toxicol 8 2012 33 42
44. S.L. Thornton, R.R. Gerona, and C.A. Tomaszewski Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification J Med Toxicol 8 2012 310 313
45. B. den Hollander, S. Rozov, A.M. Linden, M. Uusi-Oukari, I. Ojanpera, and E.R. Korpi Long-term cognitive and neurochemical effects of "bath salt" designer drugs methylone and mephedrone Pharmacol Biochem Behav 103 2013 501 509
46. T. Maurice, and T.P. Su The pharmacology of sigma-1 receptors Pharmacol Ther 124 2009 195 206
47. K.N. Cameron, R. Kolanos, E. Solis, R.A. Glennon, and L.J. De Felice Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter Br J Pharmacol 2012
48. A.W. Goddard, S.G. Ball, J. Martinez, M.J. Robinson, C.R. Yang, and J.M. Russell Current perspectives of the roles of the central norepinephrine system in anxiety and depression Depress Anxiety 27 2010 339 350
49. R.L. Carhart-Harris, L.A. King, and D.J. Nutt A web-based survey on mephedrone Drug Alcohol Depend 118 2011 19 22
50. R. Lisek, W. Xu, E. Yuvasheva, Y.T. Chiu, A.B. Reitz, and L.Y. Liu-Chen Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation Drug Alcohol Depend 126 2012 257 262
51. J.B. Robinson Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl Biochem Pharmacol 34 1985 4105 4108 (Pubitemid 16195470)
52. D. Sulzer, T.K. Chen, Y.Y. Lau, H. Kristensen, S. Rayport, and A. Ewing Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport J Neurosci 15 1995 4102 4108
53. M.S. Sonders, S.J. Zhu, N.R. Zahniser, M.P. Kavanaugh, and S.G. Amara Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants J Neurosci 17 1997 960 974 (Pubitemid 27043955)
54. H.H. Sitte, S. Huck, H. Reither, S. Boehm, E.A. Singer, and C. Pifl Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter J Neurochem 71 1998 1289 1297 (Pubitemid 28390284)